Skip to main content

Advertisement

Table 3 Effects (RR and NNT (95% CI)) obtained with different doses of anti-TNFα drugs

From: Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety

   All doses of anti-TNFα drugs vs. control 4618 vs. 2261* Recommended doses of anti-TNFα drugs vs. control 2874 vs. 2260** High-doses drugs vs. control 1169 vs. 921*** of anti-TNFα Low-doses of anti-TNFα drugs vs. control 251 vs. 252****
Anti-TNFα ACR RR (CI 95%) NNT RR (CI 95%) NNT RR (CI 95%) NNT RR (CI 95%) NNT
Adalimumab ACR20 1.9 (1.3–2.8) 6 (5–7) 2.0 (1.3–2.9) 5 (4–6) 3.5 (1.6–7.3) 3 (2–4) 2.4 (1.4–4.1) 5 (4–8)
  ACR50 2.7 (1.6–4.4) 6 (5–7) 2.8 (1.6–4.7) 5 (5–6) 4.7 (1.9–12.0) 4 (3–5) 2.9 (1.6–5.1) 7 (5–13)
  ACR70 3.3 (1.8–6.3) 9 (7–11) 3.5 (1.9–6.7) 7 (6–8) 6.1 (1.8–20.8) 7 (5–11) 3.0 (1.1–7.9) 17 (9–77)
Etanercept ACR20 1.7 (1.1–2.6) 7(5–10) 1.7 (1.1–2.7) 6 (5–8) There are no trials with high doses of Etanercept 4.3 (1.9–10.1) 3 (2–5)
  ACR50 2.1 (1.1–3.9) 6 (5–9) 2.2 (1.1–4.3) 6 (4–7)    4.7 (1.7–13.4) 6 (4–13)
  ACR70 2.0 (0.9–4.4) NS 2.1 (0.9–4.5) NS    7.4 (0.9–58.5) NS
Infliximab ACR20 1.8 (1.2–2.8) 5 (4–6) 1.7 (1.1–2.6) 5 (4–6) 2.0 (1.2–3.6) 5 (4–5) There are no trials with low doses of Infliximab
  ACR50 2.6 (1.5–4.7) 5 (5–6) 2.2 (1.2–4.1) 6 (5–7) 2.8 (1.5–5.5) 5 (4–6)   
  ACR70 2.9 (1.4–5.8) 8 (6–10) 2.4 (1.2–5.0) 9 (7–13) 3.3 (1.5–7.2) 7 (6–7)   
Overall ACR20 1.8 (1.4–2.3) 6 (5–7) 1.8 (1.4–2.3) 5 (5–6) 2.5 (1.5–4.2) 4 (5–4) 2.9 (1.7–5.1) 4 (3–6)
  ACR50 2.5 (1.8–3.4) 6 (5–6) 2.4 (1.7–3.4) 5 (5–6) 3.4 (2.0–5.8) 5 (4–5) 3.2 (2.0–5.3) 6 (5–10)
  ACR70 2.8 (1.9–4.2) 8 (7–9) 2.7 (1.8–4.1) 7 (7–9) 3.9 (2.0–7.6) 7 (6–8) 3.5 (1.4–8.6) 15 (10–38)
  1. NNT: number of patients needed to be treated
  2. RR (95%CI): relative risk (95% confidence limits)
  3. NS: non-significant results
  4. *4618 patients being treated with anti-TNFα (except 208 patients Bathon's trial being treated with 10 mg of etanercept twice a week) vs 2261 patients of the control groups
  5. **2874 patients with recommended doses of anti-TNFα drugs (Infliximab 3 mg/Kg/8 week; etanercept 25 mg twice a week; adalimumab 40 mg every 2 weeks) vs 2260 patients of the control groups
  6. ***1169 patients with high-doses of anti-TNFα drugs (infliximab 3 mg/Kg 4 week, 6 mg/Kg 8 week, 10 mg/Kg 8 week and 10 mg/Kg 4 week; adalimumab 40 mg/week, 80 mg/2 week) vs 921 patients of the control groups
  7. ****251 patients with low-doses of anti-TNFα drugs (etanercept 10 mg twice weekly; adalimumab 20 mg/2 week) vs 252 patients of the control groups